Protagonist Therapeutics 将来の成長

Future 基準チェック /16

Protagonist Therapeuticsの収益は年間2%で減少すると予測されていますが、年間収益は年間1.6%で増加すると予測されています。EPS は年間減少すると予測されています。自己資本利益率は 3 年後に32% 8.5%なると予測されています。

主要情報

-2.0%

収益成長率

-8.5%

EPS成長率

Biotechs 収益成長	27.2%
収益成長率	1.6%
将来の株主資本利益率	32.0%
アナリストカバレッジ	Good
最終更新日	21 Mar 2025

今後の成長に関する最新情報

Recent updates

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Mar 11

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up

Mar 11

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Jan 13

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Oct 16

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

業績と収益の成長予測

NasdaqGM:PTGX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2027	137	-70	-60	-133	6
12/31/2026	141	-41	-38	2	10
12/31/2025	99	-81	8	-76	10
12/31/2024	434	275	183	184	N/A
9/30/2024	324	171	229	230	N/A
6/30/2024	319	170	231	232	N/A
3/31/2024	315	162	-64	-63	N/A
12/31/2023	60	-79	-71	-70	N/A
9/30/2023	N/A	-140	-119	-119	N/A
6/30/2023	N/A	-138	-118	-117	N/A
3/31/2023	1	-140	-105	-105	N/A
12/31/2022	27	-127	-109	-108	N/A
9/30/2022	35	-130	-104	-103	N/A
6/30/2022	45	-133	-108	-107	N/A
3/31/2022	47	-122	-118	-117	N/A
12/31/2021	27	-126	-109	-108	N/A
9/30/2021	24	-108	-101	-100	N/A
6/30/2021	27	-81	-88	-88	N/A
3/31/2021	31	-70	-86	-85	N/A
12/31/2020	29	-66	-73	-72	N/A
9/30/2020	26	-65	-68	-68	N/A
6/30/2020	17	-73	-66	-66	N/A
3/31/2020	2	-83	-42	-41	N/A
12/31/2019	0	-77	-42	-42	N/A
9/30/2019	0	-74	-38	-37	N/A
6/30/2019	2	-66	-34	-32	N/A
3/31/2019	22	-45	-52	-51	N/A
12/31/2018	31	-39	-50	-50	N/A
9/30/2018	40	-28	N/A	-54	N/A
6/30/2018	43	-24	N/A	-4	N/A
3/31/2018	31	-31	N/A	-1	N/A
12/31/2017	20	-37	N/A	4	N/A
9/30/2017	9	-45	N/A	8	N/A
6/30/2017	N/A	-48	N/A	-39	N/A
3/31/2017	N/A	-40	N/A	-35	N/A
12/31/2016	N/A	-38	N/A	-30	N/A
9/30/2016	N/A	-32	N/A	-25	N/A
6/30/2016	N/A	-28	N/A	-22	N/A
3/31/2016	N/A	-24	N/A	-17	N/A
12/31/2015	N/A	-15	N/A	-14	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PTGXの収益は今後 3 年間で減少すると予測されています (年間-2% )。

収益対市場: PTGXの収益は今後 3 年間で減少すると予測されています (年間-2% )。

高成長収益: PTGXの収益は今後 3 年間で減少すると予測されています。

収益対市場: PTGXの収益 ( 1.6% ) US市場 ( 8.4% ) よりも低い成長が予測されています。

高い収益成長: PTGXの収益 ( 1.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PTGXの自己資本利益率は、3年後には高くなると予測されています ( 32 %)

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/03/23 06:41
終値	2025/03/21 00:00
収益	2024/12/31
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Protagonist Therapeutics, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。21

アナリスト	機関
Douglas Tsao	Barclays
Mayur Somaiya	BMO Capital Markets Equity Research
Etzer Darout	BMO Capital Markets Equity Research

Protagonist Therapeutics 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Recent updates

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up

Protagonist Therapeutics, Inc. Announces New Icotrokinra (Jnj-2113) Data from the Comprehensive Phase 3 Clinical Program and the Planned Initiation of the First-Ever Head-To-Head Study in Plaque Psoriasis

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Protagonist Therapeutics, Inc. Announces Transition of Suneel Gupta from Chief Development Officer to Executive Vice President, Clinical Development

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

Protagonist Therapeutics, Inc. Announces Positive Topline Results from Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113)

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Protagonist Therapeutics, Inc. Announces Publication of Phase 1 Clinical Data on JNJ-2113 in the Journal

Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Advisor, Effective August 1, 2024

Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control

Investor sentiment improves as stock rises 16%

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

CEO, President notifies of intention to sell stock

Executive VP & Chief Financial Officer recently sold US$378k worth of stock

Executive VP & Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

CEO, President notifies of intention to sell stock

Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Consensus revenue estimates increase by 102%

Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director

Chief Development Officer exercised options to buy US$282k worth of stock.

Consensus revenue estimates increase by 250%

New minor risk - Profitability

Consensus revenue estimates fall by 30%

Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director

Price target increased by 7.3% to US$39.00

Protagonist Therapeutics, Inc., Annual General Meeting, May 27, 2024

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Price target increased by 9.1% to US$37.83

Consensus revenue estimates increase by 100%

Protagonist Reports Positive Results from Phase 1 and Pre-Clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.43 loss in 1Q 2022)

Consensus revenue estimates fall by 51%

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Full year 2022 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor

Insider exercised options to buy US$812k worth of stock.

Insufficient new directors

Third quarter 2022 earnings released: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021)

Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer

Price target decreased to US$34.40

CEO, President exercised options to buy US$187k worth of stock.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

Consensus revenue estimates increase by 28%

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Price target decreased to US$48.29

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$52.00

Insufficient new directors

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

CEO, President exercised options to buy US$680k worth of stock.